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Abstract. Resistance to chloroquine (CQ) requires its replacement as first-line therapy for uncomplicated malaria in
much of Africa. Combination therapy may improve efficacy and delay the selection of resistant malaria parasites.
Combinations of sulfadoxine-pyrimethamine (SP) with 4-aminoquinolines offer affordable and available alternatives to
CQ. We conducted a randomized, single-blinded trial to compare the efficacy of SP monotherapy with combinations of
SP and either CQ or amodiaquine (AQ) for the treatment of uncomplicated falciparum malaria in patients over 6
months of age in Kampala, Uganda. Of the 448 patients enrolled, 428 (95%) completed follow-up. Clinical treatment
failure after 14 days occurred in 21/140 (15.0%, 95% CI 9.5–22.0%) SP-treated, 11/152 (7.2%, 95% CI 3.7–12.6%)
SP/CQ-treated, and 0/136 (0%, 95% CI 0–2.7%) SP/AQ-treated patients. Combination therapies were safe and offered
superior efficacy to SP monotherapy. SP/AQ was the most efficacious. This low-cost combination regimen may provide
an optimal alternative to CQ for the treatment of uncomplicated malaria in Uganda.
INTRODUCTION
Malaria remains one of the most important infectious dis-
eases worldwide. In sub-Saharan Africa, widespread resis-
tance to chloroquine (CQ), the traditional first-line therapy
for uncomplicated malaria, presents an important public
health problem. Affected countries are faced with the chal-
lenge of selecting a new first-line regimen and revising anti-
malarial treatment policies.1 There is a limited choice of avail-
able and affordable antimalarials, and the optimal alternative
to CQ is not clear. Several African countries have adopted
sulfadoxine-pyrimethamine (SP) as a replacement for CQ.2
However, the therapeutic life span of SP may be limited by
rapid emergence of resistance under intense drug pressure.
Indeed, evidence for increasing SP resistance in East Africa
has begun to emerge.3–6
Countries faced with a high prevalence of CQ-resistant ma-
laria are increasingly considering the use of combination
therapy to treat uncomplicated malaria. Combination therapy
has been advocated to improve efficacy and delay the devel-
opment and spread of drug resistance.7 The use of SP with
4-aminoquinoline antimalarials offers the only available low-
cost option for antimalarial combination therapy in Africa at
this time. In a systematic review, combinations of SP with
either CQ or amodiaquine (AQ) provided improved fever
clearance but similar treatment outcomes to SP mono-
therapy.8 However, resistance to SP was very low in these five
studies. With increasing levels of SP resistance, SP-
aminoquinoline combinations may offer more-significant ad-
vantages in therapeutic efficacy.
CQ resistance was first reported in Uganda in 1988,9 and its
prevalence appears to have risen steadily since then. In 2000,
clinical CQ resistance rates of 10–80% prompted the Ugan-
dan Ministry of Health to re-evaluate its antimalarial treat-
ment recommendations. The combination of SP/CQ was cho-
sen as the provisional replacement for first-line therapy of
uncomplicated malaria. Limited information is available re-
garding the efficacy of SP/CQ,8,10,11 but no trials with this
combination have been conducted in Uganda. Recent studies
of SP/AQ in Kampala indicated that the combination regimen
was safe and highly efficacious for the treatment of uncom-
plicated malaria.12,13 Importantly, in a longitudinal compari-
son, SP/AQ was significantly superior to SP and artesunate
(AS), an artemisinin derivative widely advocated as a potent
new antimalarial.2 Both SP/AQ and SP/AS demonstrated ex-
cellent efficacy for the treatment of uncomplicated malaria at
14 days of follow-up, but only SP/AS was associated with
frequent late-treatment failures.13 Thus, in combination with
SP, aminoquinolines may offer improved long-term efficacy,
in addition to much lower cost, when compared with AS.
To better assess the relative efficacies of aminoquinoline-
SP combinations, we conducted a randomized trial of SP,
SP/CQ, and SP/AQ for the treatment of uncomplicated ma-
laria in Kampala, Uganda.
MATERIALS AND METHODS
Subject recruitment. The study was conducted in the out-
patient department of Mulago Hospital in Kampala, Uganda
from March 2001–January 2002. Malaria is mesoendemic in
Kampala, with peak transmission occurring after the two
rainy seasons.
Consecutive patients presenting with symptoms suggesting
acute malaria and a positive screening blood smear were re-
ferred to the study clinic and assessed for eligibility using the
following inclusion criteria: 1) age over 6 months; 2) acute
uncomplicated Plasmodium falciparum monoinfection with a
parasite density of  2,000 asexual parasites/L; 3) tympanic
temperature of  38°C or history of fever in the previous 48
hrs; 4) absence of concomitant febrile illness; 5) absence of
signs and symptoms of severe malaria14 or danger signs (con-
vulsion in the previous 24 hrs, persistent vomiting, lethargy,
inability to drink); 6) absence of known allergy to sulfa drugs;
7) residence in Kampala; 8) provision of informed consent;
and 9) agreement to 2 weeks’ follow-up.
Recruited patients were interviewed about their symptoms
and history of therapy in the previous 2 weeks. A physical
examination was performed, and core temperature, height,
weight, and spleen size were measured. All temperatures
were measured using an electronic tympanic thermometer. A
documented fever was defined as a tympanic temperature of
38.0°C (equivalent to an axillary temperature of 37.5°C).
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Randomization and treatment.On the day of enroll-
ment, patients were assigned a study number and randomized
using a computer generated list to receive either a single dose
of SP (Fansidar, Roche), 25 mg/kg sulfadoxine and 1.25 mg/kg
pyrimethamine; SP plus CQ (Avloclor, Zeneca), 25mg/kg in 3
divided doses given on days 0, 1 and 2; or SP plus AQ (Camo-
quine, Parke-Davis), 25 mg/kg in 3 divided doses given on
days 0, 1 and 2. Patients randomized to receive SP were given
lactose placebo tablets in the same regimen as CQ. Placebo
tablets were not identical to study drugs. All study personnel
were blinded to treatment groups except for two nurses who
administered treatment but were not involved in outcome
assessment. Drugs were administered under direct observa-
tion; if a patient vomited within 30 minutes of treatment, the
dose was repeated. All patients were given acetaminophen
for 3 days to relieve febrile symptoms. Patients with a hemo-
globin of  10 g/dL were given ferrous sulfate and mebenda-
zole if they were older than 1 year and had not had an anti-
helminthic in the previous 6 months, according to Integrated
Management of Childhood Illnesses (IMCI) guidelines (Man-
agement of Childhood Illnesses, Ministry Of Health, 1997).
Patients who failed treatment were given quinine sulfate 10
mg/kg every 8 hours for 7 days, and those who developed
severe malaria were referred for in-patient care and paren-
teral quinine.
On day 0, all recruited patients had phlebotomy done for
confirmatory thin and thick blood smears, hemoglobin mea-
surement, and white blood cell (WBC) and neutrophil counts.
Alternate patients enrolled had serum alanine amino-
transferase (ALT) levels measured. Patients were enrolled
into the study if P. falciparum monoinfection was confirmed
with parasite density of  2,000 parasites/L. Patients were
asked to return to the study clinic for follow-up on days 1, 2,
3, 7, and 14 and any other day if they felt unwell.
Follow-up consisted of history-taking, including assessment
for adverse events, and a physical examination. A standard-
ized case record form was completed, and if an adverse event
was suspected, a separate adverse event form was completed.
On follow-up days 3 and 7, and any unscheduled days when
the patient had febrile symptoms, a fingerprick was per-
formed for a thick blood smear to assess parasitemia. On day
14, phlebotomy was done to repeat all tests performed on day
0. Patients who did not return to the clinic on a scheduled
follow-up day were visited and assessed at home. Patients
whom the home health visitor failed to locate within 24 hours
of days 1 to 3, and 48 hours of days 7 and 14, were classified
as lost to follow-up.
Patients were excluded from the study because of: 1) self-
medication with other anti-malarial drugs, 2) development of
a concomitant febrile illness that would interfere with the
malaria outcome classification, 3) withdrawal of consent, 4)
development of danger signs or severe malaria within 24
hours of enrollment.
Thick and thin smears were stained with 2% Giemsa stain
for 30 minutes, and parasite densities and gametocyte counts
were calculated based on the number of asexual parasites and
gametocytes per 200 WBCs, assuming a WBC count of 8,000/
L. Hemoglobin measurement and WBC and neutrophil
counts on days 0 and 14 were measured using a Coulter
counter. On day 0, urine was tested for the presence of 4-ami-
noquinolines and their metabolites using the Saker-Solomons
test.15
Outcome measurements. Primary outcome parameters
were clinical and parasitologic outcomes at day 14. Parasito-
logic outcomes were expressed as sensitive (S) or resistant
(RI, RII, RIII) according to the World Health Organization
(WHO) parasitologic classification system. Clinical outcomes
were classified as clinical success (adequate clinical response)
or clinical failure (early or late treatment failure) using a
slight modification of the recommended WHO clinical classi-
fication system.16 Patient report of fever in the past 48 hours
on days 4–14 in the setting of rising parasitemia was added as
a criterion for late treatment failure. Secondary outcomes
included: 1) fever (temperature greater than 38°C) clearance;
2) parasite clearance; 3) change in hemoglobin from day 0 to
day 14; and 4) appearance of gametocytes after day 0.
Tolerability of the study medication also was assessed clini-
cally and by laboratory testing. An adverse event was defined
as an unfavorable or harmful symptom or sign or an abnormal
laboratory value during or after administration of study medi-
cation. For each adverse event, causal relationship with study
medication was assessed. Adverse events determined by cli-
nicians to have an unlikely causal relationship with the study
medications were not included in the analysis. Adverse event
severity was graded as mild, moderate, or severe using the
WHO Toxicity Grading Scale and the National Institute of
Allergy and Infectious Diseases Division of Microbiology and
Infectious Diseases pediatric toxicity tables.
Statistical analysis. Sample size calculations were based on
the difference in proportion of parasitologic failure between
SP/CQ and SP alone. Expected success rates of 70% in SP-
treated and 85% in SP/CQ-treated patients, respectively,
were used. To achieve a one-sided alpha level of 5% and
power of 80%, 136 patients in each group were needed. As-
suming a 7% exclusion rate, our goal was to enroll at least 145
patients in each treatment group.
Data were entered and verified in EPI Info version 6.04
(Centers for Disease Control and Prevention, Atlanta) and
analyzed using Stata version 7.0 (Stata, College Station, TX).
Proportions were compared using 2 tests, and continuous
variables were compared using Student’s t test. Parasite den-
sities were normalized using log-transformation. All patients
with known outcomes were included in the analyses. Pairwise
comparisons among the treatment groups were planned a
priori. Subgroup analysis stratified for ages under 5 and 5 or
older were based on previous knowledge of potential effect
modification.17 Binary outcome data were analyzed by esti-
mating differences in proportions with corresponding exact
95% confidence intervals (95% CI). A P value of  0.05 was
considered statistically significant. We did not make correc-
tions for multiple comparisons.
Ethical approval. The study was approved by the Faculty
Research and Ethical Committee of Makerere University,
Kampala, the Uganda National Council for Science and Tech-
nology, and the University of California, San Francisco, Com-
mittee on Human Research.
RESULTS
Of 838 patients referred to the study clinic for evaluation,
325 were excluded during the screening interview, primarily
because of residence outside Kampala (29%), unwillingness
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to agree to 2 weeks of follow-up (27%), failure to obtain
informed consent (23%), and severe disease (10%). Of the
513 patients randomized to treatment, an additional 65 were
excluded, 35 because of initial parasitemia under 2,000/L, 25
for non-falciparum or mixed infections, and 5 for severe dis-
ease within 24 hours of enrollment (Figure 1).
Of the 448 patients enrolled, 428 (95%) successfully com-
pleted the study. Of the 20 patients (5%) who did not, nine
were treated with additional antimalarials outside the study,
five were lost to follow-up, three withdrew informed consent,
and three developed a concomitant febrile illness. Patients
who did not complete the study were similar to those who
completed it in age, initial temperature, and parasite density.
(Data not shown.) Among the three treatment groups, pa-
tients who completed the study had comparable baseline
clinical and demographic characteristics (Table 1).
The risks of clinical and parasitologic failure for the three
treatment groups are shown in Table 2. Combination thera-
pies reduced the risk of treatment failure compared with SP
monotherapy. SP/AQ significantly reduced the risk of treat-
ment failure compared with both SP monotherapy and SP/
CQ. SP/CQ significantly reduced the risk of treatment failure
compared with SP monotherapy. However, when results were
stratified by age, the difference in treatment outcome be-
tween SP/CQ and SP was significant only in children under
the age of 5 (Table 3).
Fever resolution differed in the three treatment arms. Pa-
tients receiving combination therapy were more likely to be
afebrile on day 2 compared with those in the SP monotherapy
group (Figure 2). SP/AQ-treated patients were more likely to
have no parasites in their blood by day 3 (95%) compared
with patients treated with SP/CQ (84%, P  0.005) and pa-
tients treated with SP alone (76%, P < 0.001). When compar-
ing SP/CQ to SP alone, there was no significant difference in
the proportion of patients with positive smears on day 3 (P
0.126). Six percent of patients had circulating gametocytes on
the day of enrollment, and 18% developed circulating game-
tocytes during follow-up. Appearance of gametocytes after
commencement of therapy was more common in SP-treated
patients (33%) compared with patients treated with either
SP/CQ (13%, P < 0.001) or SP/AQ (7%, P < 0.0001). There
was no statistical difference between SP/CQ- and SP/AQ-
TABLE 1
Baseline characteristics of patients who completed the study
Characteristics
SP
n  140
SP/CQ
n  152
SP/AQ
n  136
Female [% (95% CI)] 56 (47–64) 44 (36–52) 51 (42–59)
Median age [yrs (range)] 5.0 (0.6–50) 6.0 (0.5–44) 6.0 (0.5–50)
Age < 5 yrs [% (95% CI)] 47 (39–58) 44 (36–52) 43 (34–51)
History of antimalarial use in previous 2 weeks [% (95 CI)]* 53 (44–62) 48 (40–56) 61 (52–70)
Temperature  38.0°C [% (95% CI)] 38 (30–46) 39 (19–33) 40 (31–48)
Mean hemoglobin [g/dL ± SD] 9.7 ± 2.0 10.2 ± 2.4 10.2 ± 2.1
Hemoglobin  10g/dL [% (95% CI)] 55 (46–63) 48 (40–56) 49 (41–58)
Geometric mean parasite count [parasites/L (range)] 36,700 30,620 30,410
(2,000–710,000) (2,040–572,000) (2,000–1,013,760)
Parasite density > 100,000/L [% (95% CI)] 23 (16–31) 22 (15–29) 21 (15–29)
Positive urine CQ test [% (95% CI)]† 50 (40–60) 55 (46–64) 62 (51–72)
* Patients in whom data were recorded
† Patients from whom urine was obtained
FIGURE 1. Trial profile
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treated patients in the incidence of gametocytemia after
therapy (P  0.7)
For all treatment groups, the average hemoglobin levels
were higher at the end of follow-up compared with baseline.
Fifty percent, 45%, and 48% of patients randomized to re-
ceive SP, SP/CQ, and SP/AQ, respectively, were anemic (Hb
 10g/dL) at baseline. The rate of hematologic recovery in
the three groups by day 14 was 36%, 46%, and 50%, respec-
tively. The differences in recovery rates were not statistically
significant among the three groups (P  0.3)
Forty-four percent of the patients who completed the study
developed a possible adverse event during therapy or follow-
up. The most frequently reported adverse events are shown in
Table 4. Overall, the incidence of possible adverse events was
higher in patients receiving combination therapies than in
those receiving SP monotherapy. This could be explained by
a higher incidence of pruritus and nausea/vomiting in the
combination therapies. However, when mild symptoms were
eliminated from the analysis, there was no significant differ-
ence in frequency of adverse events among the three treat-
ments, and incidence did not exceed 10% for any symptom
reported in any treatment group. In addition, when adverse
events considered unlikely to be related to the study medica-
tions were included in the analysis, there was no significant
difference in number of events among the treatment groups.
(Data not shown.) One severe adverse event was reported in
an SP-treated patient: an elevated ALT measurement on day
14 of 500 IU/L (normal range 0–32) in a 3-year-old girl. On
further investigation, other liver enzymes (serum aspartate
amino-transferase, alkaline phosphatase, and gamma
glutamyl transpeptidase) also were elevated. This event was
not accompanied by symptoms and resolved without medical
intervention within 2 weeks.
DISCUSSION
In this comparative study, combinations of SP with AQ or
CQ were significantly more effective than SP monotherapy
for the treatment of uncomplicated malaria in Kampala,
Uganda. The SP/AQ combination was significantly superior
to the other regimens, providing excellent clinical (100%) and
parasitologic (99%) efficacy. SP/CQ had intermediate effi-
cacy. Compared with SP monotherapy, treatment with SP/CQ
significantly improved clinical and parasitologic outcomes
only in children younger than 5. These results show that com-
bining SP and a 4-aminoquinoline provides more-effective
treatment than SP monotherapy. In addition, they highlight
the marked superiority in efficacy of SP/AQ over SP/CQ.
Uganda is revising its national antimalarial drug policy,
which until recently recommended CQ for the treatment of
uncomplicated malaria. SP/CQ has been adopted as the pro-
visional first-line therapy. Although the SP/CQ combination
had not been studied at the time of this policy decision, it was
TABLE 2
Clinical and parasitologic treatment outcomes
SP (n  140) SP/CQ (n  152) SP/AQ (n  136)
n (%) 95% CI n (%) 95% CI n (%) 95% CI
Clinical outcomes*
ACR 119 (85%) 78–90% 141 (93%) 87–96% 136 (100%) 97–100%
ETF 7 (5%) 2–10% 3 (2%) 0–6% 0 (0%) 0–3%
LTF 14 (10%) 6–16% 8 (5%) 2–10% 0 (0%) 0–3%
Parasitologic outcomes*
S 99 (70%) 62–78% 126 (83%) 76–89% 135 (99%) 96–100%
RI 25 (17%) 12–25% 19 (13%) 8–19% 0 (0%) 0–3%
RII 11 (8%) 4–14% 5 (3%) 1–8% 1 (1%) 0–4%
RIII 5 (4%) 1–8% 2 (1%) 0–5% 0 (0%) 0–3%
ACR - adequate clinical response, ETF - early treatment failure, LTF - late treatment failure
* P-value < 0.001 for simultaneous comparisons of treatment outcomes among the three treatment groups (Pearson 2 test)
TABLE 3
Pairwise comparisons of treatment efficacy
Clinical outcome
% risk difference (95% CI)
Parasitologic outcome
% risk difference (95% CI)
All ages
SP vs. SP/CQ 7.8 (0.6–15.0) 12.2 (2.6–21.8)
SP vs. SP/AQ 15.0 (9.1–20.9) 28.6 (20.9–36.2)
SP/CQ vs. SP/AQ 7.2 (3.1–11.4) 6.4 (10.2–22.5)
Age < 5 years
SP vs. SP/CQ 12.2 (1.3–23.0) 17.0 (2.0–31.9)
SP vs. SP/AQ 18.2 (8.9–27.5) 36.4 (24.8–48.0)
SP/CQ vs. SP/AQ 6.0 (0.3–11.6) 19.4 (10.0–28.9)
Age >  5 years
SP vs. SP/CQ 3.9 (−5.6–13.4) 7.7 (−4.6–19.9)
SP vs. SP/AQ 12.2 (4.7–19.6) 21.7 (11.8–31.6)
SP/CQ vs. SP/AQ 8.2 (2.4–14.1) 14.0 (6.0–22.1)
FIGURE 2. Proportion of patients at enrollment and during the
first 3 days of follow-up with documented fever. All pairwise com-
parisons not significant (P > 0.05) except combination therapies vs
sulfadoxine-pyrimethamine (SP) alone on day 2 (SP/AQ vs SP,
P  0.002, SP/chloroquine vs SP, P  0.004).
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chosen because of the presumed benefits of combination
therapy, lingering reluctance to abandon CQ, and the lack of
available data on other antimalarial agents.18 This study of-
fers the first comparison in Uganda of the efficacies of SP
monotherapy and the SP/CQ combination.
Our study showed benefit when CQ was added to SP, with
significant but modest improvement in efficacy based on ei-
ther clinical or parasitologic criteria. However, considering
the fairly high prevalence of SP resistance demonstrated in
this and other recent studies,12,13,16 and the very high preva-
lence of CQ resistance, it seems unlikely that the addition of
CQ to SP will protect it from further selection of resistant
parasites. In contrast, as shown in other studies from Kam-
pala, the SP/AQ regimen demonstrated outstanding efficacy
against uncomplicated malaria. These data suggest that SP/
AQ, rather than SP/CQ, is the optimal available combination
regimen for the treatment of uncomplicated malaria in Kam-
pala.
For malaria transmission to occur, gametocytes must be
transmitted to anopheline mosquitoes. While highly effica-
cious drugs will reduce gametocytemia because of the rapid
reduction of circulating parasites, it has been suggested that
treatment with partially effective drugs may increase game-
tocytogenesis, and this appears to be a particular concern with
SP.19–22 In this study, the incidence of gametocytemia was
significantly higher in SP-treated patients than in either SP/
CQ- or SP/AQ-treated patients, suggesting another advan-
tage of the combination therapies over SP monotherapy.
Attributing adverse events to medications is difficult, as
many potential adverse events of antimalarial drugs are simi-
lar to signs and symptoms of malaria. Although adverse
events were reported more frequently in the combination
groups, these differences were due to adverse events of only
mild intensity. AQ and SP have both been associated with
rare but severe adverse events when used as chemoprophy-
laxis but appear to be safer when used in short-term
therapy.23–26 However, in endemic areas where people are
treated for malaria repeatedly, the risk of adverse drug reac-
tions may increase. Studies such as this one, which evaluate
treatment of a single episode of malaria, are limited in their
ability to assess the risk of adverse events with frequent an-
timalarial use. It is encouraging, therefore, that a longitudinal
study in Kampala recently noted no severe adverse events
after repeated use of SP/AQ over 1 year.13 Careful adverse
event monitoring and additional studies evaluating the effi-
cacy, safety, and tolerability of SP/AQ after repeated use will
help to more fully assess this highly effective regimen. At
present, however, it appears that any potential for increased
toxicity from SP/AQ compared with SP/CQ will be offset by
markedly improved efficacy, and thus a decreased need for
antimalarial treatment over time.
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